PSMA-PET Provides Additional Risk Stratification in High-Risk Prostate Cancer

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 9, 2025.

By Elana Gotkine HealthDay Reporter

THURSDAY, Jan. 9, 2025 -- Among patients with high-risk prostate cancer and no evidence of metastatic disease on conventional imaging, prostate-specific membrane antigen-positron emission tomography (PSMA-PET) results were positive in 84 percent of patients and detected distant metastatic disease in 46 percent, according to a study published online Jan. 3 in JAMA Network Open.

Adrien Holzgreve, M.D., from the University of California, Los Angeles, and colleagues conducted a post-hoc, retrospective cross-sectional study involving 182 patients with high-risk nonmetastatic hormone-sensitive prostate cancer after radical prostatectomy (RP), definitive radiotherapy (dRT), or salvage radiotherapy (SRT) from four prospective studies conducted from Sept. 15, 2016, to Sept. 27, 2021, to describe the staging information obtained by PSMA-PET/computed tomography.

The researchers found that the median prescan prostate-specific antigen levels were 2.4, 6.9, 2.6, and 2.8 ng/mL after RP, dRT, RP and SRT, and overall, respectively. The results of PSMA/PET were positive in 80, 92, 85, and 84 percent of patients after RP, dRT, RP and SRT, and overall, respectively. PSMA-PET detected any distant metastatic disease in 34, 56, 60, and 46 percent of patients after RP, dRT, RP and SRT, and overall, respectively. Polymetastatic disease was detected in 19, 36, 23, and 24 percent of patients after RP, dRT, RP and SRT, and overall, respectively.

"PSMA-PET provides novel additional risk stratification for patients with high-risk nmHSPC [nonmetastatic hormone-sensitive prostate cancer] without distant metastasis based on conventional imaging," the authors write. "Integration of PSMA-PET in major industry-sponsored clinical trials for secondary end points analyses is warranted."

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-01-10 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords